Fig. 1.

The number of growing published articles or studies from 1980 to Aug 2023, based on mitochondrial medicine (pink), therapies (blue), and clinical trials (green). The publications of therapeutic targets increase following the pathfinding of mitochondria-related molecular mechanisms in many pathologies, including cardiac ischemia/reperfusion (IR) injury, stroke, and nonalcoholic steatohepatitis (NASH). Interventional clinical trials investigating the therapeutic potential of targeting mitochondrial dysfunction are also witnessing a yearly increment discernible in the volume. Data for this figure was extracted from PubMed by searching the term “mitochondri*” in combination with either “medicine”, “transplantation”, “transfer”, “administration”, “delivery”, “restore”, “rescue”, “treatment”, or “therap*”. Data of active clinical trials (recruiting, not yet recruiting, active, not recruiting, completed, enrolling by invitation, unknown status) were acquired from ClinicalTrials.gov